Proactive Opioid Risk Prediction
Personalized Pain Management
Genetic signature-based prediction of opioid related risks
Personalized clinical decision support for precision pain relief
Genotype-based clinical decision support within 1-2 days
Indiana University School of Medicine
OpalGenix’s Evidence-Based and Patent Technology
OpalGenix’s GPS-Opioid™ technology was developed based on Dr. Sadhasivam’s extensive NIH-funded clinical research on opioid pharmacogenetics and personalized surgical pain management. OpalGenix’s technology received more than 10 US and European Patent Treaty Office approved patent claims.